Cell cycle dysregulation, a key feature of cancer, leads to excessive cell division. CDK4 and CDK6 are essential for cell cycle transition and crucial in breast cancer. Inhibitors for these kinases (CDK4/6i) halt tumor growth by blocking a protein (Rb). These inhibitors are used with hormone therapy for advanced breast cancer, improving patient survival. However, there’s no standard treatment for drug resistance. Recent research shows CDK4/6i can affect other cancer and surrounding tissues, offering new clinical insights. This review explores the CDK4/6-Rb-E2F pathway, CDK4/6i effects, and resistance mechanisms, highlighting new treatment opportunities.

Read more here: https://pubmed.ncbi.nlm.nih.gov/38943828/